[在炎症性肠道疾病的生物疗法期间抗体形成的频率]
Krisztián Kovács1, Petra Nagypál2, Barna Vásárhelyi1
11 Semmelweis Egyetem, Általános Orvostudományi Kar, Laboratóriumi Medicina Intézet Budapest, Nagyvárad tér 4., 14. emelet, 1089; Magyarország.
对于炎症性肠道疾病的生物疗法表现出不同的免疫性. 因弗利西马布的抗药抗体比阿达利木马布的比率更高,这凸显了监测和量身定制的治疗策略的必要性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 生物疗法,包括瘤亡因子抑制剂 (TNFi) 和其他药物,对于炎症性肠病 (IBD) 至关重要.
- 免疫性,导致抗药抗体 (ADA),限制了长期的有效性,并导致反应的二次损失.
- 对于优化IBD治疗来说,对IBD中不同生物病原体的免疫性进行真实研究的数据至关重要.
研究的目的:
- 评估和比较匈牙利常用的生物疗法的真实免疫性.
- 评估用因弗利西马布 (IFX),阿达利穆马布 (ADA),维多利祖马布 (VDZ) 和乌斯特基努马布 (UST) 治疗的患者中抗药抗体的患病率.
- 确定影响免疫性因素,如疾病特征,年龄和性别.
主要方法:
- 对153名IFX/ADA患者和183名UST/VDZ患者进行了横截面分析.
- 使用现代免疫测试技术评估了免疫性.
- 根据治疗组,疾病亚型,年龄和性别分析了数据.
主要成果:
- 在TNFi (IFX/ADA) 和其他生物制剂组 (UST/VDZ) 之间,整体抗药抗体患病率相似 (21%对20%).
- 因弗利西马布 (33.0%) 的免疫原性明显高于阿达利木马布 (12.0%).
- 乌斯特基努马布 (15.0%) 的抗体阳性率较低,而维多利祖马布 (28.0%) 的抗体阳性率较高,但不显著.
结论:
- 虽然整体免疫性看起来相似,但IBD的个别生物药物之间存在显著差异.
- 与阿达利木马布相比,因弗利西马布的免疫性更高,需要积极的治疗药物监测和潜在的组合疗法.
- 需要对vedolizumab和ustekinumab免疫性进行细微解释,考虑到短暂抗体和治疗药物监测的重要性.
更多相关视频
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Ulcerative Colitis in IBD
